Affilogic presents Nanofitins® at Adebiotech symposium
Adebiotech Symposium, October 2013
Adebiotech, a French biotechnology association, organized a conference dedicated to “innovative technologies for industrial protein purification” on October 28th, 29th and 30th 2013 at Romainville. Olivier Kitten, president of Affilogic, presented to major actors of the downstream processing industry – such as Bio-Rad, Pall Life Sciences, Sartorius Stedim Biotech, Merk Millipore, LFB Biotechnologies and Sanofi Pasteur – the affinity ligands Nanofitins® as innovative tools for custom purification.
Affilogic pushes ahead its lead towards the clinic
Abstract Biotech Finances Special Issue 2013 – n°4
“Its goal : developing oral formulations of Nanofitins® for treatment of Inflammatory Bowel Diseases, especially Crohn’s disease”
”Currently in preclinical development, the consortium, which has brought together 7 partners since the beginning of 2012, is marking a strategic shift with pending integration of a pharmaceutical partner. It is a significant industrial recognition in this highly attractive therapeutic field, allowing Affilogic to foresee a promising clinical future for its compound” (…)
Drugs of the future are discovered in Nantes
Abstract Nantes Passion April 2013
“His favorite subject ? Nanofitins®. These small proteins, coming from bacteria discovered in Yellowstone Park geysers, exhibit the same functionnalities as the antibodies produced by our body.”
“We produce them on demand to diagnose and cure diseases where antibodies are not successful.”, explains Olivier Kitten, CEO of Affilogic. After 3 years, this young biotech established in Nantes on the site of the Sciences University has generated around fifteen Nanofitins®. Seven are currently evaluated by industrials in France, in the United States or in Japan to develop new drugs against Crohn’s Disease, Psoriasis” (…)
Affilogic presents Nanofitins ® during Bio Partnering North 2013
Bio Partnering North, February 2013
On February 26, 2013, Nadège Prel, Business Development manager at Affilogic presented their Nanofitins®, proteins alternative to therapeutic antibodies at the “Partnering with France” Workshop during Bio Partnering North in Vancouver.
Affilogic presents Nanofitins® at French Embassy in Japan
Abstract Bio Nikkei February 2013
Affilogic’s founder and CEO, Olivier Kitten, presented the Nanofitins® at the French Embassy in Japan, for a partnering event organized by UBIFRANCE with Japanese pharmaceutical companies, following the BIO Asia congress on January 31st, 2013.
“(…) In 2011, Affilogic obtained a Research grant from the European Commission to develop therapeutic agents for Crohn’s disease and Ulcerative colitis. The goal of this project is to generate Nanofitins® inhibiting TNF that could be administered orally. (…) On top of oral administration, we are investigating the possibility of formulating Nanofitins® within ointments and eye drops.(…)”
Mini proteins to diagnose and cure several pathologies
Abstract La Tribune January 2013
For 3 years, the biotech company from Nantes Affilogic has been engineering Nanofitins® used as an alternative to antibodies for diagnostic applications or to treat pathologies such as Crohn’s Disease, Psoriasis, AMD (Age-related Macular Degeneration), Rheumatoid Arthritis…
(…) Seven “pilot” projects are in the hands of Pharma companies awaiting validation.
These proteins, 20 times smaller than antibodies, can be very easily conjugated with other molecules and have applications in diagnostics and for the treatment of pathologies. Cost-effective production costs could make it possible, eventually, to propose targeted and individualized treatments for same price as antibiotics. (…)”